Health Canada approves use of Jardiance for patients with CKD
Click Here to Manage Email Alerts
Key takeaways:
- Health Canada has approved the use of Jardiance for the treatment of adults with chronic kidney disease.
- More than 4 million people in Canada have CKD.
Health Canada has approved the use of Jardiance for the treatment of adults with chronic kidney disease, according to a press release.
Jardiance (empagliflozin, Boehringer Ingelheim/Eli Lilly) is a once-daily oral treatment prescribed to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular and renal death in adults with CKD. More than 4 million people in Canada have CKD, according to the release.
Empagliflozin is indicated in Canada in adults with type 2 diabetes, type 2 diabetes and established cardiovascular disease, heart failure and CKD, according to the release.
Results from the EMPA-KIDNEY trial showed that patients who took 10 mg of Jardiance reduced their risk for the primary composite endpoint (sustained 40% eGFR decline), sustained eGFR of less than 10 mL/min/1.73m², development of ESKD, renal death or CV death compared with placebo, according to the release.
Use of Jardiance also reduced the risk of all-cause hospitalization, both first and recurrent hospitalizations, by 14% compared with placebo, according to the release.
"This new treatment option has the potential to further improve the clinical care for people living with CKD by reducing the risk of kidney function loss, kidney failure, cardiovascular death and hospitalizations," David Z.I. Cherney, MD, PhD, a member of the EMPA-KIDNEY steering committee and Canadian co-national lead investigator and senior scientist at Toronto General Hospital Research Institute, said in the release. "Given the interconnectedness of cardio-renal-metabolic conditions, it is beneficial to have medicines that target the heart, kidney and endocrine system in one treatment."
Click Here to Manage Email Alerts